Bisphosphonate use in children with pediatric osteoporosis and other bone conditions.
Bisphosphonates (BPs) are used most commonly in children with osteogenesis imperfecta, resulting in increased trabeculae and cortical thickness, increased bone density as measured by DXA (Dual Energy X-ray Absorptiometry), and improved vertebral morphology. Less well documented in controlled trials are decrease in long bone fractures, improved strength and motor function, and decreased pain. Outside of children with osteogenesis imperfecta, use of bisphosphonates in children is increasing, all of which is off-label. This is seen in children with other chronic conditions resulting in pediatric osteoporosis and insufficiency fractures. Additional indications include steroid dependency with progressive loss of bone density, avascular necrosis of bone, and chronic regional pain syndrome. This review highlights the potential benefits and risks of the use of bisphosphonates in these unique children at risk for fracture or bone collapse.
['Szalay|Elizabeth A|EA|']
D015502:Absorptiometry, Photon D015519:Bone Density D002648:Child D020918:Complex Regional Pain Syndromes D004164:Diphosphonates D050723:Fractures, Bone D006801:Humans D056687:Off-Label Use D010020:Osteonecrosis D010024:Osteoporosis D010372:Pediatrics
bisphosphonates pediatric osteoporosis DXA